← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy

nivolumab plus ipilimumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationEsophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line nivolumab with ipilimumab for adults with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.

LAMPGEN ANALYSIS

Why it matters

The dual-checkpoint regimen offers a first-line option that does not use cytotoxic chemotherapy.

What research teams should watch

Identify the regimen separately from nivolumab with chemotherapy and plan follow-up for dual-checkpoint toxicities.

PRIMARY RECORDS

Sources